Marinomed Biotech AG/ ATMARINOMED6 /
| 2024-05-07 5:35:01 PM | Chg. +0.450 | Volume | Bid2024-05-07 | Ask5:45:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 17.250EUR | +2.68% | 674 Turnover: 11,471.300 |
-Bid Size: - | -Ask Size: - | 26.19 mill.EUR | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -4.50 EUR | 4.65% |
| EPS Diluted: | - EUR | 4.65% |
| Revenues per Share: | 6.05 EUR | -19.19% |
| Book Value per Share: | -6.67 EUR | 142.16% |
| Cash Flow per Share: | -2.98 EUR | -13.77% |
| Dividend per Share: | - EUR | - |
| Total | in mill. | |
| Revenues: | 9.18 EUR | -18.54% |
| Net Income: | -6.79 EUR | 6.16% |
| Operating Cash Flow: | -4.52 EUR | - |
| Cash and Cash Equivalents: | 2.58 EUR | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 2.85 | 4.83 |
| P/BV ratio: | -2.59 | -4.38 |
| P/CF Ratio: | -5.79 | -9.81 |
| PEG: | -0.82 | - |
| Earnings Yield: | -26.09% | -15.41% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 26.19 mill. EUR | 44.33 mill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | 503,631.6635 EUR | 852,524.3231 EUR |
| Shares Outstanding: | 1.52 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | -55.77% |
| Net Profit Margin: | -74.01% |
| Return on Equity: | - |
| Return on Assets: | -46.50% |
Financial Strength
| Liquidity I / Cash Ratio: | 26.74% |
| Liquidity II / Quick Ratio: | 63.32% |
| Liquidity III / Current Ratio: | 73.89% |
| Debt / Equity Ratio: | - |
| Dynam. Debt / Equity Ratio: | -547.35% |
Efficiency
| Employees: | 52 |
| Personal Expenses / Employee: | - EUR |
| Revenues / Employee: | 176,538.46 EUR |
| Net Income / Employee: | -130,653.85 EUR |
| Total Assets / Employee: | 280,961.54 EUR |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | EUR |
